GlassScriptPhysician profile
Michelle Ngo
NPI 1760773014
$16,922.72
in general payments reported to CMS, 2019-2025
31 companies · $3,207 in 2025
The $3,207 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,767 · 2020: $1,498 · 2021: $2,144 · 2022: $2,189 · 2023: $1,971 · 2024: $2,146 · 2025: $3,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,271 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,270.90 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,041.40 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $3,193.59 | 2019-2025 | |
| Janssen Biotech, INC. | $2,812.19 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,331.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,113.41 | 2019-2025 | Benlysta |
| Pfizer INC. | $866.61 | 2019-2025 | |
| Lilly USA, LLC | $684.97 | 2019-2025 | Taltz |
| Horizon Therapeutics Plc | $552.93 | 2019-2022 | |
| Radius Health, INC. | $412.54 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $289.52 | 2023-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $221.96 | 2019-2021 | |
| Celgene Corporation | $207.51 | 2019 | |
| Genzyme Corporation | $201.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.50 | 2019-2024 | Cyltezo |
| Ucb, INC. | $151.46 | 2022-2025 | Bimzelx, Cimzia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $103.07 | 2024-2025 | Lupkynis |
| Genentech USA, INC. | $89.85 | 2021-2025 | Actemra |
| Sanofi-Aventis U.S. LLC | $65.61 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $61.73 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $58.60 | 2019-2020 | |
| Genentech, INC. | $53.45 | 2025 | |
| Medexus Pharma, INC. | $52.99 | 2019-2020 | |
| Shield Therapeutics INC | $48.95 | 2025 | |
| Sobi, INC | $39.12 | 2019-2020 | |
| Assertio Therapeutics, INC. | $14.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.48 | 2019 | |
| Sandoz INC. | $13.99 | 2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $13.97 | 2020 | |
| Organon LLC | $13.36 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.26 | 2019 | |
| Zyla Life Sciences, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.